About

Changing the World’s Perspective on Breast Imaging

Our Mission

Our mission is to create a revolution in medical imaging through our advanced Computed Tomography technology, optimizing early disease detection, diagnosis, intervention and treatment. Our hope is to be able to improve survival rates and outcomes for millions of patients.

Our Vision

Our vision is to transform the breast health journey for both physicians and patients. With the Koning Vera (KBCT), we aim to give clinicians clearer, more comprehensive imaging to support confident decisions, while offering patients a more comfortable, compression-free experience. By bridging clinical precision with patient-centered care, we aspire to set a new standard in breast imaging that improves trust, access, and outcomes.

Koning Revolutionary Technology

2002
2002

Dr. Ning founds Koning with exclusive license from University of Rochester

Koning Corporation is founded as a Delaware C corporation and receives exclusive license from the University of Rochester for Cone Beam CT and Cone Beam Breast CT technology.

2006
2006

Designs and starts clinical trials of first KBCT prototype

With the scientific and engineering experience from the previous cone beam CT systems, Dr. Ning and his group designed the first commercial grade Cone Beam Breast CT specifically for breast imaging.

This is the first time true three-dimensional, isotropic tomography images were introduced to breast imaging.

2008
2008

Secures $3.2M of US funding to accelerate development

2010
2010

First clinical paper published showing positive results from 2006-2008 clinical trials

2012
2012

Received CE mark for first production unit

2017
2017

Commercial version of KBCT approved by FDA

2018
2018

Commercial version of KBCT approved by CFDA

Regulatory approval recieved for Canada, Singapore, Australia, Thailand, and Qatar

2020
2020

AMA authorizes dedicated breast CT CPT code for diagnostic use

2023
2023

Received PMA for second generation production unit